Estradiol-Producing Ovarian Tumors in Postmenopausal Women
Granulosa cell tumors are the most common estradiol-producing ovarian tumors in postmenopausal women, though sex cord-stromal tumors (including thecomas, Sertoli-Leydig cell tumors, and steroid cell tumors), ovarian tumors with functioning stroma, and rarely neuroendocrine tumor metastases can also produce estradiol.
Primary Estrogen-Producing Tumors
Sex Cord-Stromal Tumors (Most Common)
Granulosa cell tumors are the predominant estrogen-producing ovarian neoplasms and account for the majority of ovarian tumors with endocrine manifestations 1. These tumors:
- Occur most frequently in peri- and postmenopausal women
- Are "typically oestrogenic" and associated with various clinical syndromes depending on patient age 1
- Present with postmenopausal bleeding due to endometrial stimulation 2
- Can be confirmed using immunopanel of inhibin alpha, calretinin, and FOXL2, along with FOXL2 (402C-G) mutational analysis 1
Thecomas also produce estrogen and occur mainly in peri- and postmenopausal women 1.
Steroid cell tumors (not otherwise specified) can produce excessive estrogen, though they more commonly produce testosterone 3, 4. When estrogen-producing, they present with:
- Postmenopausal vaginal bleeding
- Elevated serum estradiol levels (e.g., 393.71 nmol/l in one case) 3
- Cells with granular eosinophilic or vacuolated cytoplasm
- Strong inhibin positivity on immunohistochemistry 3
Sertoli-Leydig cell tumors typically produce androgens causing virilization in 70%-85% of patients 1, but rare cases present with hyperestrogenism instead 5. These occult lesions:
- May be too small to detect on imaging
- Present with postmenopausal bleeding and elevated estradiol (e.g., 75.64 pg/mL)
- Require high clinical suspicion when hyperestrogenism occurs without virilization 5
Ovarian Tumors with Functioning Stroma
Any ovarian tumor can develop functioning stroma capable of estrogen production 6. In a study of 20 postmenopausal cases:
- Tumor types included mucinous, endometrioid, clear cell, Brenner tumors, carcinosarcoma, and Krukenberg tumor
- Serum estradiol ranged widely from 12.1 to 162.4 pg/mL (reference: 10-30 pg/mL)
- Both lutein-like and theca-like stromal cells expressed P450 aromatase, enabling conversion of androgens to estrogens
- No correlation existed between stromal cell morphology and estradiol levels 6
Critical pitfall: These tumors may show no ovarian enlargement on imaging, making preoperative diagnosis challenging 7, 5.
Rare Stromal Tumors
Sclerosing stromal tumor is exceptionally rare but can produce estrogen 7. One case demonstrated:
- Postmenopausal bleeding with thickened endometrium
- Elevated estradiol (49.78 ng/L; normal <27.25 ng/L)
- 3 cm solid ovarian tumor
- Estradiol normalized within 3 days post-oophorectomy, confirming tumor source 7
Metastatic Tumors
Neuroendocrine tumor metastases to the ovary represent a novel syndrome of estradiol overproduction 8. In this 2024 study:
- 21% (14/66) of postmenopausal patients with ovarian NET localizations reported vaginal bleeding
- Ovarian vein sampling confirmed ovarian estrogen production
- Estrogen levels normalized after oophorectomy
- Immunohistochemistry showed marked aromatase expression in NET cells
- This represents a newly recognized NET-associated hormonal syndrome 8
Diagnostic Algorithm
When evaluating postmenopausal bleeding with elevated estradiol:
- Measure serum estradiol and testosterone - both can be elevated depending on tumor type
- Perform pelvic ultrasound and CT/MRI - but recognize that tumors may be occult or too small to visualize 7, 5
- Consider hormonal evaluation even with normal imaging if clinical suspicion remains high 7
- Assess for virilization signs - absence doesn't exclude sex cord-stromal tumors 5
- Evaluate for primary neuroendocrine tumor if ovarian mass appears metastatic 8
- Obtain tissue diagnosis with immunohistochemistry (inhibin, calretinin, FOXL2, aromatase) to confirm tumor type 1
The key clinical caveat is that normal imaging does not exclude an estrogen-producing ovarian tumor - hormonal evaluation should guide surgical exploration when clinical and biochemical evidence suggests ovarian estrogen excess 7, 5.